Finance

Lists
2096:HKG
Simcere Pharmaceutical Group Ltd
11,02 HK$
+1,75%
(+0,19) 1D
16 հոկ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 2096...
Open
10,85 HK$
High
11,29 HK$
Low
10,85 HK$
Mkt. cap
28,30 մլրդ
Avg. vol.
4,02 մլն
Volume
5,80 մլն
Dividend
1,88%
Quarterly dividend
0,05 HK$
Ex-dividend date
18 հնս, 2025 թ.
P/E ratio
16,54
52-wk high
14,38 HK$
52-wk low
9,07 HK$
EPS
0,67 HK$
Shares outstanding
2,57 մլրդ
No. of employees
7 հզր
Open
10,85 HK$
High
11,29 HK$
Low
10,85 HK$
Mkt. cap
28,30 մլրդ
Avg. vol.
4,02 մլն
Volume
5,80 մլն
Dividend
1,88%
Quarterly dividend
0,05 HK$
Ex-dividend date
18 հնս, 2025 թ.
P/E ratio
16,54
52-wk high
14,38 HK$
52-wk low
9,07 HK$
EPS
0,67 HK$
Shares outstanding
2,57 մլրդ
No. of employees
7 հզր
News stories
From web sources and news partners
Profile
Simcere Pharmaceutical Group or Simcere Pharmaceutical is a manufacturer and supplier of branded generic pharmaceuticals in the Chinese market. Its focus is to introduce generic and pharmaceutical products for the treatment of diseases with high incidence and/or mortality rate. The company has introduced a generic anti-stroke medication under the brand name, Bicun, and an anti-cancer medication under the brand name, Endu. Its products include antibiotics, anti-stroke medications, anti-inflammatory drugs, anti-cancer medications and other medicines. In addition, it has obtained approvals from the China State Food and Drug Administration to manufacture and sell over 210 other products. Wikipedia
About Simcere Pharmaceutical Group Ltd
CEORen Jinsheng
Employees7,06 հզր
Founded1995
HeadquartersՆանջին, Jiangsu, Չինաստան
Sector-
Previous reports
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
2,07 մլրդ
2,07 մլրդ
2,29 մլրդ
2,29 մլրդ
Cost of goods sold
365,25 մլն
365,25 մլն
382,55 մլն
382,55 մլն
Cost of revenue
365,25 մլն
365,25 մլն
382,55 մլն
382,55 մլն
Research and development expenses
465,30 մլն
465,30 մլն
412,46 մլն
412,46 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
949,52 մլն
949,52 մլն
1,01 մլրդ
1,01 մլրդ
Operating expense
1,36 մլրդ
1,36 մլրդ
1,39 մլրդ
1,39 մլրդ
Total operating expenses
1,72 մլրդ
1,72 մլրդ
1,77 մլրդ
1,77 մլրդ
Operating income
351,33 մլն
351,33 մլն
520,99 մլն
520,99 մլն
Other non operating income
-
-
-
-
EBT including unusual items
425,92 մլն
425,92 մլն
483,36 մլն
483,36 մլն
EBT excluding unusual items
348,89 մլն
348,89 մլն
531,61 մլն
531,61 մլն
Income tax expense
55,72 մլն
55,72 մլն
70,09 մլն
70,09 մլն
Effective tax rate
13,08%
13,08%
14,50%
14,50%
Other operating expenses
-56,27 մլն
-56,27 մլն
-42,94 մլն
-42,94 մլն
Net income
370,20 մլն
370,20 մլն
414,36 մլն
414,36 մլն
Net profit margin
17,86%
17,86%
18,09%
18,09%
Earnings per share
-
-
-
-
Interest and investment income
14,60 մլն
14,60 մլն
24,20 մլն
24,20 մլն
Interest expense
-23,63 մլն
-23,63 մլն
-24,61 մլն
-24,61 մլն
Net interest expenses
-9,03 մլն
-9,03 մլն
-416,00 հզր
-416,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
449,72 մլն
449,72 մլն
606,04 մլն
606,04 մլն
Gain or loss from assets sale
-115,50 հզր
-115,50 հզր
-
-
AI content may include mistakes. Learn more
Google Apps